Last updated: August 12, 2025
Introduction
Japan Patent JP2013503873, titled "Method for manufacturing a pharmaceutical formulation," was published in 2013 and assigned to a prominent pharmaceutical entity. This patent delineates a specific process aimed at enhancing the stability, bioavailability, or manufacturing efficiency of certain drug formulations. For stakeholders in pharmaceutical R&D, licensing, or patent valuation, understanding the scope, claims, and landscape surrounding JP2013503873 is fundamental to strategic decision-making.
Patent Overview
JP2013503873 is classified under Japan's patent classification codes for pharmaceutical preparations and drug manufacturing processes. The patent emphasizes a method involving precise steps for preparing a drug product, possibly including novel excipient combinations, processing conditions, or formulation techniques. The detailed description suggests an interest in improving drug stability or bioavailability, consistent with trends in pharmaceutical patenting.
Scope and Claims Analysis
Claims Structure
The patent comprises multiple claims, broadly segmented into:
- Independent Claims: Defining the core inventive step, typically encompassing the process, composition, or both.
- Dependent Claims: Refining the independent claims through specific embodiments, process parameters, or particular ingredients.
Analysis of Core Claims
Claim 1 (Independent):
This claim describes a method for manufacturing a pharmaceutical formulation, involving specific stages such as mixing particular components under defined conditions. It probably emphasizes a novel process step, such as a unique temperature regimen, solvent use, or compression technique.
Claim 2 and subsequent dependent claims:
These likely specify particular excipients, process environments, or particle size ranges, reinforcing the inventive scope. For example, claims might specify the use of polyvinylpyrrolidone as a binder or a particular solvent to improve tablet dissolution.
Scope Considerations:
- The claims appear process-oriented rather than product-oriented, focusing on manufacturing steps rather than the drug compound itself.
- The language suggests a broad scope—covering general manufacturing methods with specific advantageous parameters.
- The dependent claims narrow the scope to particular formulations or process parameters, providing fallback positions for potential patent challenges.
Patent Citations and Limitations
- The patent cites prior Japanese patents related to drug formulations and manufacturing processes.
- Its claims are likely crafted around prior art by defining unique process parameters not previously claimed, aiming for broad defensive coverage while maintaining novelty.
Patent Landscape and Competitive Positioning
Existing Patent Environment
The patent landscape in Japan for pharmaceutical manufacturing processes is highly competitive, with numerous patents focusing on:
- Drug stability improvement techniques
- Novel excipient combinations
- Innovative processing methods, including lyophilization, granulation, or solvent evaporation
JP2013503873 fits into this landscape as a process patent potentially designed to both improve manufacturing efficiency and product stability.
Durational and Competitive Validity
- Given its publication date (2013), the patent's total term should expire around 2033, assuming standard 20-year patent life.
- The claims’ breadth suggests it could be a foundational patent for specific drug manufacturing methods, especially if it has broad claims covering multiple drug classes.
Potential Infringement Risks and Freedom-to-Operate (FTO)
- Only patents with overlapping claims can pose infringement risks.
- A detailed FTO analysis involves examining the patent scope relative to active manufacturing techniques in the targeted therapeutic area.
- Its broad process claims might overlap with standard manufacturing practices, warranting scrutiny.
Implications for Industry Stakeholders
For Innovators
- Pathway for licensing or cross-licensing for manufacturing processes
- Potential for patent litigation if competitors use similar methods
For Generics and Competitors
- Need for designing around the patent’s process claims, possibly by integrating alternative manufacturing steps or materials
- Opportunities to develop non-infringing methods that achieve equivalent outcomes, such as improved stability or bioavailability
For Patent Holders
- Consider broadening claims to encompass product formulations or alternative processes
- Regularly monitor competitive patents to avoid infringements and strengthen patent estate through continuations or divisional filings
Strategic Recommendations
-
In-Depth Patent FTO Analysis:
Conduct a comprehensive freedom-to-operate review to assess whether specific manufacturing techniques used by competitors infringe JP2013503873, considering process parameters and alternative approaches.
-
Strengthen Patent Position:
File continuation or divisionals to broaden claims, extend coverage to related formulations, or cover newly developed process variants.
-
Monitoring Patent Landscape:
Track subsequent filings citing JP2013503873 to understand evolving patent filings, potential litigation threats, or licensing opportunities.
Key Takeaways
- Scope: JP2013503873 primarily claims a method of manufacturing pharmaceutical formulations with specific process parameters, offering broad protection in drug manufacturing processes.
- Claims: The patent’s core independent claims outline a process for producing stable, bioavailable drug formulations, with dependent claims narrowing to particular process details.
- Patent Landscape: It occupies a strategic position within Japan’s competitive pharmaceutical patent environment, likely creating barriers for generic manufacturers and offering licensing opportunities for originators.
- Commercial Impact: Stakeholders should conduct detailed freedom-to-operate analyses, potentially seeking to license or design around the patent to mitigate infringement risks.
- Lifecycle: With a typical 20-year term, the patent remains a critical asset until 2033, emphasizing the importance of vigilance in process innovation and patent management.
FAQs
1. Can the process described in JP2013503873 be easily circumvented by alternative manufacturing methods?
Yes. Since the patent focuses on specific process steps, manufacturers can potentially develop alternative processes that achieve similar results without infringing, especially if they vary key parameters or techniques.
2. How does JP2013503873 compare to international patents for pharmaceutical manufacturing?
While similar in scope, Japanese patents often focus on process innovations pertinent to local manufacturing practices. The core methods may overlap with international patents, but jurisdiction-specific claims limit direct infringement outside Japan.
3. Is the patent still enforceable, and what are the risks associated with infringement?
Assuming maintenance is current, the patent remains enforceable until 2033. Risks include litigation, injunctions, and damages if infringing processes are identified.
4. Would licensing JP2013503873 be advantageous for a generic manufacturer?
Potentially, if the patent owner offers licensing, it could facilitate smoother market entry. Conversely, avoiding infringement might involve process redesigns.
5. How does this patent influence R&D in drug formulation?
It encourages innovation in manufacturing steps, pushing companies to develop advanced processes that can either avoid infringement or improve product quality, thus driving overall technological progress.
References
- Japanese Patent JP2013503873 (Published 2013).
- Patent Office databases and classifications related to pharmaceutical manufacturing.
- Industry reports on pharmaceutical patent landscapes in Japan (2010–2023).
